Having trouble accessing articles? Reset your cache.

Seattle Genetics gains on brentuximab data

Seattle Genetics Inc. (NASDAQ:SGEN) gained $2.14 (18%) to $14.30 on Monday after it and partner Millennium Pharmaceuticals

Read the full 171 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE